European Heart Journal (2013) 34, 809815 doi:10.

1093/eurheartj/ehs046

REVIEW

Clinical update

Importance and management of chronic sleep apnoea in cardiology

Leeor M. Jaffe 1,2, John Kjekshus 1,2, and Stephen S. Gottlieb 1,2*
1

School of Medicine, University of Maryland, 22 S. Greene St, Baltimore, MD 21201, USA; and 2Rikshospitalet University Hospital, University of Oslo, Oslo, Norway

Received 28 June 2011; revised 14 December 2011; accepted 9 February 2012; online publish-ahead-of-print 16 March 2012

Sleep apnoea is a common, yet underestimated, chronic disorder with a major impact on morbidity and mortality in the general population. It is quickly becoming recognized as an independent risk factor for cardiovascular impairment. Hypertension, coronary artery disease, diabetes, cardiovascular rhythm and conduction abnormalities, cerebrovascular disease, and heart failure have all been linked to this syndrome. This review will explore the critical connection between sleep apnoea and chronic cardiovascular diseases while highlighting established and emerging diagnostic and treatment strategies.

----------------------------------------------------------------------------------------------------------------------------------------------------------Keywords
Sleep apnoea Heart failure Hypoxaemia Cardiovascular disease

Introduction
Sleep apnoea is a common, yet underestimated, chronic disorder with a major impact on morbidity and mortality in the general population. It is quickly becoming recognized as an independent risk factor for cardiovascular impairment. Hypertension, coronary artery disease (CAD), diabetes, cardiovascular rhythm and conduction abnormalities, cerebrovascular disease, and heart failure (HF) have all been linked to this syndrome. This review will explore the critical connection between sleep apnoea and chronic cardiovascular diseases while highlighting established and emerging diagnostic and treatment strategies.

Classication
Sleep apnoea describes a syndrome of nocturnal respiratory interruptions resulting in sleep fragmentation, daytime hypersomnolence, and oxyhaemoglobin desaturation, usually unrecognized by the patient.1 The severity of sleep apnoea is commonly quantied by the apnoea-hypopnoea index (AHI), which is the number of apnoeic and hypopnoeic events per hour. An AHI of 5 15 indicates mild disease, 15 30 indicates moderate disease, and . 30 indicates severe disease. The prevalence of sleep apnoea in the general population appears surprisingly high, even when bias is taken into account in both the selection of subjects referred for sleep studies and their willingness to participate. Sleep apnoea,

of any degree, was reported to be present in 17% of adults according to one study, and moderate to severe sleep apnoea (AHI 15) in 5.7%.2 Other studies found the prevalence of moderate sleep apnoea to be between 1 and 14%. It is reasonable to assume that 1 in 5 adults has at least mild sleep apnoea, and 1 in 15 adults has at least moderate sleep apnoea.3 The sleep apnoea syndrome can be divided into obstructive sleep apnoea (OSA), central sleep apnoea (CSA), and the combination of the two. Obstructive sleep apnoea is caused by nocturnal upper airway collapse with preserved breathing efforts during apnoea. The risk of OSA rises with increasing body weight; active smoking; diabetes; age; and inuence of alcohol, sedatives, and muscle relaxants.4 Central sleep apnoea, also clinically known as Cheyne-Stokes respiration, is a result of decreased ventilatory drive, mainly due to loss of ne tuning of the breathing control system. It is especially common in patients with heart failure or stroke when the voluntary respiratory control is disabled during sleep.5 Patients with CSA have enhanced chemoreceptor sensitivity.6 Relatively minor increases in nocturnal PaCO2 can cause an exaggerated hyperventilatory response, often driving PaCO2 below the apneoic threshold. The resulting apnoea causes CO2 to build up, perpetuating the cycle. A prolonged circulation time may further delay chemoreceptor response to hypoxia and hypercapnia, further desynchronizing the circulatory, respiratory, and neurological systems7 (Figure 1).

* Corresponding author. Tel: + 1 410 328 8788, Fax: + 1 410 328-1048, Email: sgottlie@medicine.umaryland.edu Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2012. For permissions please email: journals.permissions@oup.com

810

L.M. Jaffe et al.

Figure 1 Mechanisms leading to the development and propagation of central sleep apnoea. Deregulation of the pulmonary and nervous systems lead to haemodynamic derangements, hypoxia, and hypercapnoea.147

Some patients have both types of respiratory sleep disorder. They are, for the most part, patients with long-standing OSA or heart failure who have developed chronic malfunctioning of the respiratory regulatory system.1

Pathophysiology of chronic sleep apnoea

Patients with sleep apnoea suffer a host of haemodynamic and biochemical derangements.8 Obstructive sleep apnoea causes sharp decreases in intrathoracic pressure which increases venous return, results in an acute leftward intraventricular septal shift, alters transmural cardiac pressures, impairs left ventricular lling, increases myocardial oxygen demand,9 and causes ischaemia.10 In addition, haemodynamic derangements and the stress of frequent awakenings lead to increased catecholamine release by stimulating central and peripheral chemoreceptors and eliminating the reex inhibition of sympathetic activity.11 Hypoxaemia and retention of CO2 in sleep apnoea cause chemoreex-mediated increases in

sympathetic activity with consequent vasoconstriction and acceleration of the heart rate.12 This can lead to marked uctuations in blood pressure.13 15 Changes in oxygenation and intrathoracic pressure have also been associated with acute changes in pulmonary vascular resistance. Pulmonary artery pressure increases over the course of an apnoeic episode due to a combination of progressive hypoxia, decreased intrathoracic pressure, increased right heart output, and decreased left heart compliance16 (Figure 2). Furthermore, hypoxia activates nucleated cells in the body, which sense and respond to reduced oxygen tension.17 The condition stimulates transcription factors such as hypoxia-inducible factor 1 (HIF-1) and nuclear factor kB (NF-kB) which regulate the expression of genes that mediate inammatory responses.8,17 This process generates reactive oxygen species that consume intravascular nitric oxide (NO), and impair endothelial-mediated vasodilation.18 Nuclear factor kB orchestrates the expression of cytokines [tumour necrosis factor (TNF)-alpha, IL-6, and IL-8], adhesion molecules (VCAM-1, E- and L-selectin, ICAM-1, and CD15), and cyclo-oxygenase enzymes (cyclo-oxygenase 1).19,20

Importance and management of chronic sleep apnoea

811

Figure 2 Effects of obstructive sleep apnoea on pulmonary and nervous systems. These derangements lead to systemic organ damage via inammatory mediators.

Hypoxia-inducible factor 1 promotes angiogenesis and can potentiate atherosclerosis by stimulating vascularization within the atherosclerotic plaque.21 24 Inammatory cytokines enhance the survival of myeloid inammatory cells, such as granulocytes, monocytes, and macrophages, increasing their functional longevity and inammation.17 Sleep apnoea is independently associated with higher levels of C-reactive protein, IL-6, IL-8, IL-18, TNF-alpha, homocystine, leptin, and matrix metalloproteinase-9.25 30 The severity of sleep apnoea, and, particularly, the severity of oxyhaemoglobin desaturation, is linked to increased levels of TNF-alpha and IL-6, cytokines which relate to hyperglycaemia, increased basal beta-cell function, insulin resistance, and overt type 2 diabetes.31 35 In patients with type 2 diabetes, OSA is associated with poorer glucose control measured by HgB A1C, independent of adiposity and other confounders.36 Cross-sectional studies have shown a correlation between hyperlipidaemia and sleep apnoea, with obesity as a possible confounder.37,38 Animal models have demonstrated a direct link between hypoxia and elevated cholesterol and liver triglyceride content.39 Sleep apnoea may even play a role in the development of non-alcoholic steatohepatitis (NASH), with one study nding the prevalence of sleep apnoea to be near 50% in patients with NASH.40,41

Inammation provoked by chronic sleep apnoea might cause considerable endothelial damage. Sleep apnoea patients have increased numbers of circulating apoptotic endothelial cells compared with controls. These levels correlate with abnormal brachial artery ow-mediated dilation, a marker of endothelial dysfunction.42 Increased intima-media thickness, associated with higher levels of C-reactive protein, IL-6, and IL-18, is also strongly related to the duration of nocturnal oxyhaemoglobin desaturation.43,44 This vascular compromise is a common pathway for the development of multi-organ dysfunction (Figure 3).

Hypertension
Large cross-sectional and longitudinal studies have shown a strong correlation between chronic sleep apnoea and arterial hypertension, independent of potential confounders.45 47 A large prospective study also demonstrated a strong association between the presence of sleep apnoea and the development of hypertension.48 A distinct feature of sleep apnoea-induced hypertension is loss of the normal nocturnal decrease in blood pressure. This indicates a link between these two disorders.49 Intermittent hypoxia and reoxygenation, as well as the stress of haemodynamic derangements and frequent awakenings, lead to

812

L.M. Jaffe et al.

Figure 3 Postulated mechanisms underlying the relationship between sleep apnoea and cardiac disease. Note the many mechanisms (third level) by which hypoxaemia may lead to cardiovascular abnormalities. established.57 59 In one study, sleep apnoea was found in 65.7% of patients admitted to the hospital for acute myocardial infarction (MI).60 The co-existence of CAD and sleep apnoea portends a poor prognosis with a large prospective study demonstrating a 70% relative and a 10.7% absolute increase in death, cerebrovascular events, and MIs compared with those having CAD alone.61 A similar study demonstrated that in patients treated successfully with percutaneous coronary intervention after an ACS, the presence of sleep apnoea was associated with higher mortality (38 vs. 9%), increased rate of stent restenosis (24 vs. 5%), and increased rate of major adverse cardiac events (37 vs. 15%) within 1 year.62 Optimal treatment of sleep apnoea may have important clinical implications for patients with refractory angina. A small study done on patients who suffered from nocturnal angina showed that 9 out of 10 patients were suffering from sleep apnoea, with a consistent temporal association between apnoeic episodes and the onset of angina. The administration of CPAP diminished the number of anginal episodes and the number of nocturnal myocardial ischaemic events.63 There are also case reports of patients suffering

decreased NO levels, higher catecholamine levels, and increased blood pressure. These changes are partially reversible with continuous positive airway pressure (CPAP) therapy as demonstrated by numerous well designed randomized, controlled studies.50 53 Treatment is especially important in cases of resistant hypertension since more than 80% of these patients have been reported to have sleep apnoea.47 The relationship between sleep apnoea and hypertension may be even more complex. Resistant hypertension is highly correlated with hyperaldosteronism, which promotes accumulation of uid within the neck and can worsen sleep apnoea. Moreover, increasing evidence suggests that blocking aldosterone in patients with resistant hypertension can both improve the severity of sleep apnoea while decreasing blood pressure.54 56

Coronary artery disease and acute coronary syndrome

The correlation between sleep apnoea and the development of CAD and acute coronary syndrome (ACS) has been well

Importance and management of chronic sleep apnoea

813

from typical angina symptoms, without critical CAD seen on cardiac catheterization, who were found to be suffering from sleep apnoea.64 Although treatment of sleep apnoea has not been shown to reverse progression of CAD, it might retard its progression. Treatment of sleep apnoea with CPAP can decrease the rate of occurrence of new cardiovascular events in patients with known CAD.65 The results from the large Randomized Intervention with CPAP in Coronary Artery Disease and Sleep Apnoea (RICCADSA trial) are still pending but will soon help to shed light on the benet of CPAP in this population.66 Sleep apnoea increases blood coagulability and viscosity,67 These patients have increased platelet aggregability, higher levels of clotting factors, and reduced brinolytic capacity.68 These ndings could, in addition to contributing to CAD progression, predispose to thrombus formation and in-stent thrombosis.

Heart failure
Sleep apnoea is extremely common in people with heart failure. Estimates of prevalence are as high as 4776%.85 88 Alarmingly, one study reported an average AHI of 44 in HF patients with sleep apnoea.88 The relationship between sleep apnoea and HF is complex. Chronic sleep apnoea causes a series of derangements that could potentially lead to the development or exacerbation of HF. Hypoxaemia, often aggravated by coexisting anaemia, is linked with acute increases in BNP concentrations in patients with HF, independent of the frequency of apnoeic events.89 Furthermore, hypertension, CAD, diabetesall well established risk factors for HFare adversely impacted by sleep apnoea. Sleep apnoea induced increase in sympathetic tone and heart rate are especially detrimental in HF. The heightened level of stimulation is maladaptive to an already failing heart and can lead to myocyte injury, cardiac beta-adrenoreceptor desensitization, and functional and structural abnormalities.90 Studies have also shown that higher sympathetic activity is associated with worse outcomes in HF.91,92 Updated HF guidelines are beginning to stress the importance of carefully screening and treating HF patients for sleep apnoea.93 Heart failure can both cause and exacerbate OSA and CSA, initiating a potentially devastating cycle. The severity of HF, as measured by cardiac index, correlates with the degree of CSA.4,95 Fluid shifts while supine result in increased neck vein congestion, neck circumference, pharyngeal airow resistance, and pharyngeal collapsibility, all of which cause obstructive symptoms.96 HF is also linked with Cheyne-Stokes respiration; animal models suggest that pulmonary congestion activates lung vagal irritant receptors, which causes hyperventilation and decreased CO2, as well as stretch receptors, which elicits a strong inhibitory reex (Hering Breuer ination reex). This reex results in a cessation of breathing followed by a period of arousal and hyperventilation that further destabilizes breathing.97,98 In addition, prolonged circulation time may play a role, with the increase in circulatory delay in HF patients altering physiological feedback mechanisms99 (Figure 1). Cheyne-Stokes respirations are a powerful independent predictor of poor prognosis in patients with CHF.100 Patients with severe heart failure can even experience Cheyne-Stokes respirations during daytime. This phenomenon is associated with higher levels of biomarkers of cardiac dysfunction and is an independent predictor of mortality.101,102 It is important to note that the classic symptoms of Cheyne-Stokes respiration, which are fragmented sleep, paroxysmal nocturnal dyspnoea, orthopnoea, and daytime fatigue, can easily be interpreted as worsening HF symptoms.103 Treatment of CSA may improve HF symptoms and quality of life. Diastolic dysfunction is also highly correlated with sleep disordered breathing and nocturnal hypoxaemia.104 107 The prevalence of sleep apnoea in patients who have HF with preserved ejection has been reported to be as high as 70%, with a predominance of OSA.108 The cause of the link between OSA and diastolic dysfunction is not well dened, and could be related to hypertension, obesity, ischaemic heart disease, or other factors.

Arrhythmia
Sleep apnoea is associated with hypoxia, autonomic derangements, and cardiac structural changes, all of which predispose to arrhythmia. Cross-sectional studies have indicated a strong association between atrial brillation (AF) and sleep apnoea, independent of age, sex, hypertension, HF, and body mass index.69 These studies have reported a sleep apnoea prevalence of 4373% among those with AF, with high rates of CAD and CSA in this group.70 The degree of nocturnal hypoxia was also shown to be directly correlated with the risk of developing AF.71,72 Hypoxia causes autonomic abnormalities, diastolic dysfunction, and systemic inammation leading to cardiac remodelling and alterations in cardiac conduction leading to the development of AF.72,73 The presence of OSA portends a 25% greater risk of AF recurrence after catheter ablation.74 Treatment with CPAP prior to an ablation procedure is associated with an eight-fold improvement in the lasting success of this procedure.75,76 Sleep apnoea, especially in association with HF, has been linked to a host of other cardiac dysrhythmias, including nocturnal paroxysmal asystole, bradyarrythmias, atrioventricular nodal block, supraventricular tachycardia, and non-sustained ventricular tachycardia.77 People with OSA have dramatically increased risk of sudden cardiac death during sleep. This risk was clearly associated with the AHI.78 A study of HF sufferers with implanted debrillators further demonstrated that sleep disordered breathing is associated with an increased incidence of malignant ventricular arrhythmias.79 A similar study demonstrated a predominance of nocturnal life-threatening ventricular arrhythmias in sleep apnoea patients with no signicant increase in daytime arrhythmic activity.80 Treatment with CPAP decreases nocturnal rates of sinus bradycardia, sinus pauses, paroxysmal AF, premature ventricular contractions, and ventricular ectopy.81 83 In one study, CPAP completely eliminated pathologically signicant nocturnal rhythm disturbances in seven of eight patients.84

814

L.M. Jaffe et al.

Pulmonary hypertension
Classically, sleep apnoea has been associated with pulmonary hypertension (PH) and cor pulmonale. Indeed, after excluding people with primary lung diseases, the prevalence of PH is 15 20% in sleep apnoea patients.109 The development of PH is not, however, related to the severity of sleep apnoea symptoms,109,110 and it is uncertain how often the sleep apnoea or the concomitant abnormalities are the cause. For example, nearly half of sleep apnoea patients with PH have increased pulmonary capillary wedge pressure, suggesting left heart dysfunction.111 In other patients, the presence of PH appears to be related to the amount of sleep time with oxygen saturation , 90%.112,113 Continuous positive airway pressure shows some benet in reversing pulmonary arterial hypertension. In the only controlled trial of CPAP which specically looked at pulmonary artery pressures, effective CPAP reduced average pulmonary systolic pressure by 5 mmHg.114

Management
Once sleep apnoea has been diagnosed, the rst remedial steps involve eliminating aggravating factors. This includes avoidance of alcohol or sedating medications, elevation of the head of the bed, and change of sleeping position to ones side to prevent the tongue from falling back and obstructing the airway. Patients should also be encouraged to lose weight. A 10% weight reduction correlated with a 26% decrease in AHI in a population-based study.120 HF treatment should be optimized with an emphasis on minimizing extravascular uid accumulation with effective diuresis.121 Angiotensin-converting enzyme inhibitors and betablockers have both been shown to reduce CSA in CHF, presumably by improving the underlying HF.122,123 The standard treatment for patients diagnosed with OSA is nocturnal CPAP usually delivered via a tight tting nasal mask. Continuous positive airway pressure should be offered to all patients diagnosed with OSA, as the benets of CPAP in this population are unquestionable. Continuous positive airway pressure therapy has been shown to lower blood pressure,124reduce cardiac rhythm disturbances,84 decrease cholesterol,40 improve insulin resistance and management of diabetes,125,126 reduce the levels of inammatory cytokines, reverse autonomic derangement,28,49 and improve endothelial function.127 Several long-term studies have also reported that CPAP reduces the incidence of cardiovascular disease and improves long-term cardiovascular morbidity and mortality among patients with severe sleep apnoea.61,128 Heart failure patients require special consideration due to the high incidence of both OSA and CSA. In those with a predominance of OSA, CPAP once again has shown some benet, although evidence of long-term improvements in morbidity and mortality from randomized controlled trials is lacking. Studies have shown that CPAP decreases sympathetic activation, improves systolic function, signicantly reduces the left ventricular end-systolic diameter, and improves quality of life.129 131 In one study, CPAP improved the left ventricular ejection fraction from an average of 25 to 33.8%.130 The treatment of CSA in HF is controversial. Since CSA is likely a manifestation of advanced HF, optimizing medical management of HF may improve symptoms of CSA. The largest randomized study, Canadian Continuous Positive Airway Pressure for Patients With CSA and HF (CANPAP), demonstrated no effect on heart transplant-free survival, but this trial was underpowered. It did, however, demonstrate improvements in apnoea frequency, blood oxygenation, norepinephrine levels, and LV function.132 Other assisted breathing devices have shown promising results. Flow-targeted dynamic bilevel positive airway pressure (BPAP), which modulates inspiratory pressure in order to maintain a target inspiratory airow has been shown to be especially effective in CSA. That is likely due to the associated pulmonary oedema and reduced lung compliance which can be impacted by BPAP.133 Adaptive servo-ventilation (ASV) therapy is a new positive airway pressure technology that tracks a patients breathing pattern and adjusts breath-by-breath pressure support to counterbalance the uctuations in respiratory rate. It will decrease the rate of pressure supported ventilation during periods of hyperventilation and

Diagnosis
The wide range of possible severe consequences of untreated sleep apnoea mandates prompt diagnosis. The gold standard is monitored polysomnography in a sleep laboratory. This modality uses multiple biometric recording devices to accurately quantify the number of apnoea (a 90% reduction in tidal volume lasting . 10 s) and hypopnoea (a reduction in tidal volume of 50 90%, lasting . 10 s accompanied by . 3% decrease in oxyhaemoglobin saturation) episodes occurring during a nights sleep. Despite the high sensitivity and specicity of polysomnography referral for a sleep study is often difcult, inconvenient, and expensive. For this reason, a number of ambulatory screening systems have been devised. Some devices can record information on multiple data sets including respiratory pattern, respiratory effort, pulse oximetry, heart rate, and peripheral arterial tone. Other devices record only one signal. In general, the more complex devices can obtain very high positive predictive values at the expense of negative predictive values,15 whereas more basic devices, such as nocturnal oximetry, are highly effective at ruling out sleep apnoea (negative predictive value 96.9%)116 but suffer in terms of their ability to reliably conrm the diagnosis. Recent studies show that for selected patients with a high pre-test probability of having sleep apnoea, home-based diagnostic and monitoring systems are not inferior to conventional hospitalbased polysomnographic diagnosis, with signicantly lower cost.117,118 Moreover, a home-based approach to diagnosis and treatment may facilitate remote monitoring and may promote greater compliance. The Portable Monitoring Task Force of the American Academy of Sleep Medicine recommends that unattended portable monitoring for the diagnosis of OSA should be performed in conjunction with a comprehensive sleep evaluation. They also recommend that portable monitoring should be used as an alternative to polysomnography only in patients with high pre-test probability of moderate to severe OSA.119

Importance and management of chronic sleep apnoea

815

Table 1

Summary of treatment modalities and outcomes in obstructive and central sleep apnoeas
Effect

........................................................................................................................................... ...............................................................................................................................................................................
Weight loss Optimization of heart failure CPAP Improvement in sleep apnoea symptoms and AHI No clear benet Proven benet in terms of AHI as well as cardiovascular morbidity and mortality Comparable efcacy to CPAP No proven benet Improvement in central sleep apnoea and decrease in heart failure-related morbidity and mortality No proven decrease in morbidity and mortality; likely improvements in apnoea frequency, blood oxygenation, norepinephrine levels, and LV function Questionably more benecial than CPAP in reducing symptoms and AHI; no data on relative improvements in morbidity and mortality Favourably compares to CPAP in terms of markers of cardiac function as well as symptom reduction; no denitive data on improvement in morbidity and mortality Some benet reported in nocturnal desaturation and periodic breathing, but no proven benet in cardiac function, morbidity, or mortality (currently not recommended) No proven or theoretical benet Intervention Obstructive sleep apnoea Central sleep apnoea

BiPap

ASV

No clear advantage over CPAP

Nocturnal oxygen supplementation Behavioural modications, muscle training, surgery Phrenic nerve stimulation

Less effective than CPAP in reduction of symptoms or AHI (currently not recommended) Some benet in decreasing AHI and symptoms, no proven improvement in cardiovascular morbidity or mortality No proven or theoretical benet

Immediate decrease in apnoea frequency and nocturnal desaturations: long-term data lacking

increase the rate during apnoeas. In non-blinded studies, ASV improved markers of cardiac function (LVEF, NYHA class, NT-pro BNP, C-reactive protein) as well as quality of life, exercise capacity, and respiratory stability in HF patients with Cheyne-Stokes respiration, comparing favourably to CPAP.134 139 A study of ASV in people with complex sleep apnoea (HF patients who developed CSA while being treated with CPAP for OSA) showed similar benets in terms of cardiac function and respiratory stability.140 Although long-term outcome data for ASV are currently lacking, trials are underway. Since the use of nocturnal supplemental oxygen signicantly reduces apnoea-related hypoxia in CSA,141,142 theoretically this might lead to long-term benet. Studies to date have shown some benet in terms of ameliorating nocturnal desaturations and periodic breathing, but no benet in terms of cardiac function, morbidity, or mortality.143,144 Current guidelines do not recommend the use of oxygen therapy in sleep apnoea, as supplemental oxygen alone may prolong apnoeas and may potentially worsen nocturnal hypercapnia in patients with co-morbid respiratory disease.99 For patients unable to tolerate CPAP therapy, less effective options have shown some benet, including behavioural treatments, dental appliances that prevent the jaw from sliding backwards, and surgery of the soft palate and nasoskeleton to open the posterior airway passage.99 Voice exercises, neck muscle strengthening manoeuvers, and even playing the didgeridoo (an indigenous Australian wind instrument) have been shown to improve the symptoms of moderate sleep apnoea.145 An exciting new modality in the pipeline is transvenous phrenic nerve electrostimulation to stimulate diaphragmatic motion in CSA.146 While clinical trials are still ongoing, preliminary data appear promising (Table 1).

Conclusion
Sleep apnoea is a common chronic disorder with potentially devastating consequences. It induces numerous physical and biochemical derangements. Sleep apnoea is pro-inammatory, with nocturnal oxygen desaturations and hypercapnia appearing to play a pivotal role in this process. It is independently associated with an increased risk of death of any cause.147 Sleep apnoea even poses a societal risk since sufferers are prone to sleepdeprived driving accidents. Diagnosis and management of sleep apnoea can be difcult. Symptoms of sleep apnoea are not easily indentied, and as many as 80% of sufferers remain undiagnosed.148 This diagnostic gap should begin to close as awareness rises of the high prevalence of sleep apnoea in many common diseases. High-risk patients for sleep apnoea include the obese, those with treatment refractory hypertension, type 2 diabetes, CAD, stroke, MIs, congestive HF, AF, nocturnal dysrhythmias, and PH. Even the gold standards of diagnosis and treatment suffer from major drawbacks. Polysomnography is expensive and inconvenient, and successful CPAP treatment is often hindered by frequent intolerance and widespread non-compliance. Sleep apnoea is one of the most prevalent and dangerous cardiac risk factors, and future research will hopefully shed more light on the effects of this disease, as well as provide more effective options for management and treatment. Conict of interest: none declared.

References
1. Hauri PJ, ed. The International Classication of Sleep Disorders, Diagnostic and Coding Manual. 2nd ed. Westchester, IL: American Academy of Sleep Medicine, 2005.

815a
2. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328: 1230 1235. 3. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:1217 1239. 4. Malhotra A, White DP. Obstructive sleep apnoea. Lancet 2002;360:237 245. 5. Lanfranchi PA, Somers VK, Braghiroli A, Corra U, Eleuteri E, Giannuzzi P. Central sleep apnea in left ventricular dysfunction: prevalence and implications for arrhythmic risk. Circulation 2003;107:727 732. 6. Narkiewicz K, van de Borne PJ, Pesek CA, Dyken ME, Montano N, Somers VK. Selective potentiation of peripheral chemoreex sensitivity in obstructive sleep apnea. Circulation 1999;99:1183 1189. 7. Javaheri S. A mechanism of central sleep apnea in patients with heart failure. N Engl J Med 1999;341:949 954. 8. Bonsignore MR, Marrone O, Insalaco G, Bonsignore G. The cardiovascular effects of obstructive sleep apnoeas: analysis of pathogenic mechanisms. Eur Respir J 1994;7:786 805. 9. Virolainen J, Ventila M, Turto H, Kupari M. Effect of negative intrathoracic pressure on left ventricular pressure dynamics and relaxation. J Appl Physiol 1995;79: 455 460. 10. Scharf SM, Graver LM, Balaban K. Cardiovascular effects of periodic occlusions of the upper airways in dogs. Am Rev Respir Dis 1992;146:321 329. 11. Somers VK, Mark AL, Zavala DC, Abboud FM. Inuence of ventilation and hypocapnia on sympathetic nerve responses to hypoxia in normal humans. J Appl Physiol 1989;67:2095 2100. 12. Somers VK, Mark AL, Zavala DC, Abboud FM. Contrasting effects of hypoxia and hypercapnia on ventilation and sympathetic activity in humans. J Appl Physiol 1989;67:2101 2106. 13. Brooks D, Horner RL, Kozar LF, Render-Teixeira CL, Phillipson EA. Obstructive sleep apnea as a cause of systemic hypertension. Evidence from a canine model. J Clin Invest 1997;99:106 109. 14. Lesske J, Fletcher EC, Bao G, Unger T. Hypertension caused by chronic intermittent hypoxiainuence of chemoreceptors and sympathetic nervous system. J Hypertens 1997;15:1593 1603. 15. Loredo JS, Ziegler MG, Ancoli-Israel S, Clausen JL, Dimsdale JE. Relationship of arousals from sleep to sympathetic nervous system activity and BP in obstructive sleep apnea. Chest 1999;116:655 659. 16. Golbin JM, Somers VK, Caples SM. Obstructive sleep apnea, cardiovascular disease, and pulmonary hypertension. Proc Am Thorac Soc 2008;5:200 206. 17. Garvey JF, Taylor CT, McNicholas WT. Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inammation. Eur Respir J 2009;33:1195 1205. 18. Eltzschig HK, Carmeliet P. Hypoxia and inammation. N Engl J Med 2011;364: 656 665. 19. Ryan S, McNicholas WT, Taylor CT. A critical role for p38 map kinase in NF-kB signaling during intermittent hypoxia/reoxygenation. Biochem Biophys Res Commun 2007;355:728 733. 20. Htoo AK, Greenberg H, Tongia S, Chen G, Henderson T, Wilson D, Liu SF. Activation of nuclear factor kappaB in obstructive sleep apnea: a pathway leading to systemic inammation. Sleep Breath 2006;10:43 50. 21. Yuan G, Khan SA, Luo W, Nanduri J, Semenza GL, Prabhakar NR. Hypoxia-inducible factor 1 mediates increased expression of NADPH oxidase-2 in response to intermittent hypoxia. J Cell Physiol 2011;226: 2925 2933. 22. Semenza GL, Prabhakar N. HIF-1-dependent respiratory, cardiovascular, and redox responses to chronic intermittent hypoxia. Antioxid Redox Signal 2007;9: 1391 1396. 23. Cramer T, Yamanishi Y, Clausen BE, Fo rster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, Firestein GS, Gerber HP, Ferrara N, Johnson RS. HIF-1alpha is essential for myeloid cell-mediated inammation. Cell 2003;112:645 657. Erratum in Cell 2003;113:419. 24. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol 2009;218:7 29. 25. Lui MM, Lam JC, Mak HK, Xu A, Ooi C, Lam DC, Mak JC, Khong PL, Ip MS. C-reactive protein is associated with obstructive sleep apnea independent of visceral obesity. Chest 2009;135:950 956. 26. Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, Hirano T, Adachi M. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003;107:1129 1134. 27. Kokturk O, Ciftci TU, Mollarecep E, Ciftci B. Elevated C-reactive protein levels and increased cardiovascular risk in patients with obstructive sleep apnea syndrome. Int Heart J 2005;46:801809.

L.M. Jaffe et al.

28. Kokturk O, Ciftci TU, Mollarecep E, Ciftci B. Serum homocysteine levels and cardiovascular morbidity in obstructive sleep apnea syndrome. Respir Med 2006;100:536 541. 29. Ye J, Liu H, Li Y, Liu X, Zhu JM. Increased serum levels of C-reactive protein and matrix metalloproteinase-9 in obstructive sleep apnea syndrome. Chin Med J (Engl) 2007;120:1482 1486. 30. Ciftci TU, Kokturk O, Bukan N, Bilgihan A. The relationship between serum cytokine levels with obesity and obstructive sleep apnea syndrome. Cytokine 2004;28:8791. 31. Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002; 165:670 676. 32. Punjabi NM, Sorkin JD, Katzel LI, Goldberg AP, Schwartz AR, Smith PL. Sleepdisordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med 2002;165:677 682. 33. Pallayova M, Steele KE, Magnuson TH, Schweitzer MA, Hill NR, Bevans-Fonti S, Schwartz AR. Sleep apnea predicts distinct alterations in glucose homeostasis and biomarkers in obese adults with normal and impaired glucose metabolism. Cardiovasc Diabetol 2010;9:83. 34. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 1997;82:4167 4170. 35. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000;11:212217. 36. Aronsohn RS, Whitmore H, Van Cauter E, Tasali E. Impact of untreated obstructive sleep apnea on glucose control in type 2 diabetes. Am J Respir Crit Care Med 2010;181:507 513. 37. Newman AB, Nieto FJ, Guidry U, Lind BK, Redline S, Pickering TG, Quan SF. Relation of sleep-disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. Am J Epidemiol 2001;154:50 59. 38. Robinson GV, Pepperell JC, Segal HC, Davies RJ, Stradling JR. Circulating cardiovascular risk factors in obstructive sleep apnea: data from randomized controlled trials. Thorax 2004;59:777782. 39. Li J, Thorne LN, Punjabi NM, Sun CK, Schwartz AR, Smith PL, Marino RL, Rodriguez A, Hubbard WC, ODonnell CP, Polotsky VY. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 2005;97:698 706. 40. Singh H, Pollock R, Uhanova J, Kryger M, Hawkins K, Minuk GY. Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2005;50:2338 2343. F, Gagnadoux F, Chazouille ` res O, Fleury B, Wendum D, Lasnier E, 41. Tanne Lebeau B, Poupon R, Serfaty L. Chronic liver injury during obstructive sleep apnea. Hepatology 2005;41:1290 1296. 42. El Solh AA, Akinnusi ME, Baddoura FH, Mankowski CR. Endothelial cell apoptosis in obstructive sleep apnea: a link to endothelial dysfunction. Am J Respir Crit Care Med 2007;175:1186 1191. 43. Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger EM, Lorenzi-Filho G. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2005;172:613618. 44. Minoguchi K, Yokoe T, Tazaki T, Minoguchi H, Tanaka A, Oda N, Okada S, Ohta S, Naito H, Adachi M. Increased carotid intima-media thickness and serum inammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 2005;172:625 630. 45. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, DAgostino RB, Newman AB, Lebowitz MD, Pickering TG. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000;283:1829 1836. 46. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. Br Med J 2000;320:479 482. 47. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, Leung RS, Bradley TD. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001;19:2271 2277. 48. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342:1378 1384. 49. Loredo JS, Ancoli-Israel S, Dimsdale JE. Sleep quality and blood pressure dipping in obstructive sleep apnea. Am J Hypertens 2001;14(9 Pt 1):887 892. 50. Becker HF, Jerrentrup A, Ploch T, Grote L, Penzel T, Sullivan CE, Peter JH. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003;107:68 73. 51. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling JR, Davies RJ. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002;359:204210. 52. Faccenda JF, Mackay TW, Boon NA, Douglas NJ. Randomized placebocontrolled trial of continuous positive airway pressure on blood pressure in

Importance and management of chronic sleep apnoea

815b
Canby R, Bailey S, Burkhardt JD, Natale A. Safety and efcacy of pulmonary vein antral isolation in patients with obstructive sleep apnea: the impact of continuous positive airway pressure. Circ Arrhythm Electrophysiol 2010;3:445 451. Bitter T, No lker G, Vogt J, Prinz C, Horstkotte D, Oldenburg O. Predictors of recurrence in patients undergoing cryoballoon ablation for treatment of atrial brillation: the independent role of sleep-disordered breathing. J Cardiovasc Electrophysiol 2012;23:18 25. Roche F, Xuong AN, Court-Fortune I, Costes F, Pichot V, Duverney D, le my JC. Relationship among the severity of Vergnon JM, Gaspoz JM, Barthe sleep apnea syndrome, cardiac arrhythmias, and autonomic imbalance. Pacing Clin Electrophysiol 2003;26:669 677. Gami AS, Howard DE, Olson EJ, Somers VK. Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med 2005;352:1206 1214. Bitter T, Westerheide N, Prinz C, Hossain MS, Vogt J, Langer C, Horstkotte D, Oldenburg O. Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-debrillator therapies in patients with congestive heart failure. Eur Heart J 2011;32:61 74. Zeidan-Shwiri T, Aronson D, Atalla K, Blich M, Suleiman M, Marai I, Gepstein L, Lavie L, Lavie P, Boulos M. Circadian pattern of life-threatening ventricular arrhythmia in patients with sleep-disordered breathing and implantable cardioverter-debrillators. Heart Rhythm 2011;8:657 662. Javaheri S. Effects of continuous positive airway pressure on sleep apnea and ventricular irritability in patients with heart failure. Circulation 2000;101: 392 397. Ryan CM, Usui K, Floras JS, Bradley TD. Effect of continuous positive airway pressure on ventricular ectopy in heart failure patients with obstructive sleep apnoea. Thorax 2005;60:781 5. Abe H, Takahashi M, Yaegashi H, Eda S, Tsunemoto H, Kamikozawa M, Koyama J, Yamazaki K, Ikeda U. Efcacy of continuous positive airway pressure on arrhythmias in obstructive sleep apnea patients. Heart Vessels 2010;25:63 69. Harbison J, OReilly P, McNicholas WT. Cardiac rhythm disturbances in the obstructive sleep apnea syndrome: effects of nasal continuous positive airway pressure therapy. Chest 2000;118:591 595. Sin DD, Fitzgerald F, Parker JD, Newton G, Floras JS, Bradley TD. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 1999;160:1101 1106. Vazir A, Hastings PC, Dayer M, McIntyre HF, Henein MY, Poole-Wilson PA, Cowie MR, Morrell MJ, Simonds AK. A high prevalence of sleep disordered breathing in men with mild symptomatic chronic heart failure due to left ventricular systolic dysfunction. Eur J Heart Fail 2007;9:243 250. Javaheri S. Sleep disorders in systolic heart failure: a prospective study of 100 male patients. The nal report. Int J Cardiol 2006;106:2128. Javaheri S, Parker TJ, Liming JD, Corbett WS, Nishiyama H, Wexler L, Roselle GA. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences and presentations. Circulation 1998;97:2154 2159. Gottlieb JD, Schwartz AR, Marshall J, Ouyang P, Kern L, Shetty V, Trois M, Punjabi NM, Brown C, Najjar SS, Gottlieb SS. Hypoxia, not the frequency of sleep apnea, induces acute hemodynamic stress in patients with chronic heart failure. J Am Coll Cardiol 2009;54:1706 1712. Floras JS. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol 1993;22:72A 84A. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995;26:1257 1263. Cohn JN. Abnormalities of peripheral sympathetic nervous system control in congestive heart failure. Circulation 1990;82(2 Suppl):I59 I67. McKelvie RS, Moe GW, Cheung A, Costigan J, Ducharme A, Estrella-Holder E, Ezekowitz JA, Floras J, Giannetti N, Grzeslo A, Harkness K, Heckman GA, Howlett JG, Kouz S, Leblanc K, Mann E, OMeara E, Rajda M, Rao V, Simon J, Swiggum E, Zieroth S, Arnold JM, Ashton T, DAstous M, Dorian P, Haddad H, Isaac DL, Leblanc MH, Liu P, Sussex B, Ross HJ. The 2011 Canadian Cardiovascular Society heart failure management guidelines update: focus on sleep apnea, renal dysfunction, mechanical circulatory support, and palliative care. Can J Cardiol 2011;27:319 338. Solin P, Bergin P, Richardson M, Kaye DM, Walters EH, Naughton MT. Inuence of pulmonary capillary wedge pressure on central apnea in heart failure. Circulation 1999;99:1574 1579. Oldenburg O, Bitter T, Wiemer M, Langer C, Horstkotte D, Piper C. Pulmonary capillary wedge pressure and pulmonary arterial pressure in heart failure patients with sleep-disordered breathing. Sleep Med 2009;10:726 730. Yumino D, Redol S, Ruttanaumpawan P, Su MC, Smith S, Newton GE, Mak S, Bradley TD. Nocturnal rostral uid shift: a unifying concept for the pathogenesis

53.

54.

55.

56.

57.

58.

59.

60.

61.

62.

63. 64.

65.

66.

67.

68.

69.

70.

71. 72.

73.

74.

75.

the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med 2001;163: 344 348. Suzuki M, Otsuka K, Guilleminault C. Long-term nasal continuous positive airway pressure administration can normalize hypertension in obstructive sleep apnea patients. Sleep 1993;16:545 549. Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. J Hum Hypertens 2011; http://dx.doi.org/10.1038/jhh.2011.47 [Epub ahead of print] Thomopoulos C, Michalopoulou H, Kasiakogias A, Kefala A, Makris T. Resistant hypertension and obstructive sleep apnea: the sparring partners. Int J Hypertens 2011;2011:947246. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Coeld SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007;131:453 459. Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, OConnor GT, Boland LL, Schwartz JE, Samet JM. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001;163:19 25. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365:1046 1053. Savransky V, Nanayakkara A, Li J, Bevans S, Smith PL, Rodriguez A, Polotsky VY. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med 2007;175:1290 1297. Lee CH, Khoo SM, Tai BC, Chong EY, Lau C, Than Y, Shi DX, Lee LC, Kailasam A, Low AF, Teo SG, Tan HC. Obstructive sleep apnea in patients admitted for acute myocardial infarction. Prevalence, predictors, and effect on microvascular perfusion. Chest 2009;135:1488 1495. Mooe T, Franklin KA, Holmstro m K, Rabben T, Wiklund U. Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am J Respir Crit Care Med 2001;164:1910 1913. Yumino D, Tsurumi Y, Takagi A, Suzuki K, Kasanuki H. Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. Am J Cardiol 2007; 99:2630. Franklin KA, Nilsson JB, Sahlin C, Naslund U. Sleep apnoea and nocturnal angina. Lancet 1995;345:1085 1087. Loui WS, Blackshear JL, Fredrickson PA, Kaplan J. Obstructive sleep apnea manifesting as suspected angina: report of three cases. Mayo Clin Proc 1994;69: 244 248. ` re R, Foucher A, de Roquefeuil F, Aegerter P, Jondeau G, Milleron O, Pillie Raffestin BG, Dubourg O. Benets of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study. Eur Heart J 2004;25:728734. Peker Y, Glantz H, Thunstro m E, Kallryd A, Herlitz J, Ejdeba ck J. Rationale and design of the randomized intervention with cpap in coronary artery disease and sleep apnoeaRICCADSA trial. Scand Cardiovasc J 2009;43:24 31. Nobili L, Schiavi G, Bozano E, De Carli F, Ferrillo F, Nobili F. Morning increase of whole blood viscosity in obstructive sleep apnea syndrome. Clin Hemorheol Microcirc 2000;22:21 27. Sanner BM, Konermann M, Tepel M, Groetz J, Mummenhoff C, Zidek W. Platelet function in patients with obstructive sleep apnoea syndrome. Eur Respir J 2000; 16:648 652. Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T, Somers VK. Obstructive sleep apnea, obesity, and the risk of incident atrial brillation. J Am Coll Cardiol 2007;49:565 571. Altmann DR, Ullmer E, Rickli H, Maeder MT, Sticherling C, Schaer BA, Osswald S, Ammann P. Clinical impact of screening for sleep related breathing disorders in atrial brillation. Int J Cardiol 2012;154:256 258. Sinno H, Derakhchan K, Libersan D, Merhi Y, Leung TK, Nattel S. Atrial ischemia promotes atrial brillation in dogs. Circulation 2003;107:1930 1936. Mehra R, Benjamin EJ, Shahar E, Gottlieb DJ, Nawabit R, Kirchner HL, Sahadevan J, Redline S, Sleep Heart Health Study. Association of nocturnal arrhythmias with sleep-disordered breathing: the Sleep Heart Health Study. Am J Respir Crit Care Med 2006;173:910 916. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inammatory mechanisms and persistence of atrial brillation. Circulation 2001;104:2886 2891. Ng CY, Liu T, Shehata M, Stevens S, Chugh SS, Wang X. Meta-analysis of obstructive sleep apnea as predictor of atrial brillation recurrence after catheter ablation. Am J Cardiol 2011;108:47 51. Patel D, Mohanty P, Di Biase L, Shaheen M, Lewis WR, Quan K, Cummings JE, Wang P, Al-Ahmad A, Venkatraman P, Nashawati E, Lakkireddy D, Schweikert R, Horton R, Sanchez J, Gallinghouse J, Hao S, Beheiry S, Cardinal DS, Zagrodzky J,

76.

77.

78. 79.

80.

81.

82.

83.

84.

85.

86.

87. 88.

89.

90. 91.

92. 93.

94.

95.

96.

815c
of obstructive and central sleep apnea in men with heart failure. Circulation 2010; 121:1598 1605. Bradley TD, Floras JS. Sleep apnea and heart failure: Part II: central sleep apnea. Circulation 2003;107:1822. Paintal AS. Vagal sensory receptors and their reex effects. Physiol Rev 1973;53: 159 227. Epstein LJ, Kristo D, Strollo PJ Jr, Friedman N, Malhotra A, Patil SP, Ramar K, Rogers R, Schwab RJ, Weaver EM, Weinstein MD, Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009;5:263. Lanfranchi PA, Braghiroli A, Bosimini E, Mazzuero G, Colombo R, Donner CF, Giannuzzi P. Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation 1999;99:1435 1440. La Rovere MT, Pinna GD, Maestri R, Robbi E, Mortara A, Fanfulla F, Febo O, Sleight P. Clinical relevance of short-term day-time breathing disorders in chronic heart failure patients. Eur J Heart Fail 2007;9:949 954. Poletti R, Passino C, Giannoni A, Zyw L, Prontera C, Bramanti F, Clerico A, Piepoli M, Emdin M. Risk factors and prognostic value of daytime Cheyne-Stokes respiration in chronic heart failure patients. Int J Cardiol 2009;137:4753. Naughton M, Benard D, Tam A, Rutherford R, Bradley TD. Role of hyperventilation in the pathogenesis of central sleep apneas in patients with congestive heart failure. Am Rev Respir Dis 1993;148:330 338. Kraiczi H, Caidahl K, Samuelsson A, Peker Y, Hedner J. Impairment of vascular endothelial function and left ventricular lling: association with the severity of apnea-induced hypoxemia during sleep. Chest 2001;119:1085 1091. Fung JW, Li TS, Choy DK, Yip GW, Ko FW, Sanderson JE, Hui DS. Severe obstructive sleep apnea is associated with left ventricular diastolic dysfunction. Chest 2002;121:422 429. Usui Y, Takata Y, Inoue Y, Tomiyama H, Kurohane S, Hashimura Y, Kato K, Saruhara H, Asano K, Shiina K, Yamashina A. Severe obstructive sleep apnea impairs left ventricular diastolic function in non-obese men. Sleep Med 2011; http://dx.doi.org/10.1016/j.sleep.2010.09.014 [Epub ahead of print]. vy P, Vautrin E, Pierre H, Ormezzano O, Baguet JP, Barone-Rochette G, Le pin JL. Left ventricular diastolic dysfunction is linked to severity of obstructive Pe sleep apnoea. Eur Respir J 2010;36:1323 1329. Bitter T, Faber L, Hering D, Langer C, Horstkotte D, Oldenburg O. Sleepdisordered breathing in heart failure with normal left ventricular ejection fraction. Eur J Heart Fail 2009;11:602 608. Kessler R, Chaouat A, Weitzenblum E, Oswald M, Ehrhart M, Apprill M, Krieger J. Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences. Eur Respir J 1996;9:787 794. Bady E, Achkar A, Pascal S, Orvoen-Frija E, Laaban JP. Pulmonary arterial hypertension in patients with sleep apnoea syndrome. Thorax 2000;55:934 939. e E, Ehrhart M, Ratomaharo J, Weitzenblum E, Krieger J, Apprill M, Valle Oswald M, Kurtz D. Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am Rev Respir Dis 1988;138:345 349. Krieger J, Sforza E, Apprill M, Lampert E, Weitzenblum E, Ratomaharo J. Pulmonary hypertension, hypoxemia, and hypercapnia in obstructive sleep apnea patients. Chest 1989;96:729 737. Sajkov D, Cowie RJ, Thornton AT, Espinoza HA, McEvoy RD. Pulmonary hypertension and hypoxemia in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1994;149:416 422. a-R o F, Alonso-Ferna ndez A, Mart nez I, Villamor J. Pulmonary Arias MA, Garc hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. Eur Heart J 2006;27: 1106 1113. Flemons WW, Littner MR, Rowley JA, Gay P, Anderson WM, Hudgel DW, McEvoy RD, Loube DI. Home diagnosis of sleep apnea: a systematic review of the literature. An evidence review cosponsored by the American Academy of Sleep Medicine, the American College of Chest Physicians, and the American Thoracic Society. Chest 2003;124:1543 1579. rie ` s F, Marc I, Cormier Y, La Forge J. Utility of nocturnal home oximetry for Se case nding in patients with suspected sleep apnea hypopnea syndrome. Ann Intern Med 1993;119:449453. Andreu AL, Chiner E, Sancho-Chust JN, Pastor E, Llombart M, Gomez-Merino E, F. Effect of an ambulatory diagnostic and treatment program in Senent C, Barbe patients with sleep apnoea. Eur Respir J 2012;39:305 312. Mulgrew AT, Fox N, Ayas NT, Ryan CF. Diagnosis and initial management of obstructive sleep apnea without polysomnography: a randomized validation study. Ann Intern Med 2007;146:157 166. Collop NA, Anderson WM, Boehlecke B, Claman D, Goldberg R, Gottlieb DJ, Hudgel D, Sateia M, Schwab R, Portable Monitoring Task Force of the American Academy of Sleep Medicine. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients.

L.M. Jaffe et al.

97. 98. 99.

120.

121.

122.

100.

123. 124.

101.

125.

102.

126.

103.

127.

104.

105.

128.

106.

129.

107.

130.

108.

131.

109.

132.

110. 111.

133.

134.

112.

135.

113.

136.

114.

115.

137.

138.

116.

139.

117.

140.

118.

141.

119.

142.

Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2007;3:737 747. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000;284: 3015 3021. Bucca CB, Brussino L, Battisti A, Mutani R, Rolla G, Mangiardi L, Cicolin A. Diuretics in obstructive sleep apnea with diastolic heart failure. Chest 2007; 132:440 446. Walsh JT, Andrews R, Starling R, Cowley AJ, Johnston ID, Kinnear WJ. Effects of captopril and oxygen on sleep apnoea in patients with mild to moderate congestive cardiac failure. Br Heart J 1995;73:237 241. Tamura A, Kawano Y, Kadota J. Carvedilol reduces the severity of central sleep apnea in chronic heart failure. Circ J 2009;73:295 298. Bazzano LA, Khan Z, Reynolds K, He J. Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. Hypertension 2007;50:417 423. Babu AR, Herdegen J, Fogelfeld L, Shott S, Mazzone T. Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. Arch Intern Med 2005;165:447 452. Hassaballa HA, Tulaimat A, Herdegen JJ, Mokhlesi B. The effect of continuous positive airway pressure on glucose control in diabetic patients with severe obstructive sleep apnea. Sleep Breath 2005;9:176 180. Ohike Y, Kozaki K, Iijima K, Eto M, Kojima T, Ohga E, Santa T, Imai K, Hashimoto M, Yoshizumi M, Ouchi Y. Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressurepossible involvement of nitric oxide and asymmetric NG, NG-dimethylarginine. Circ J 2005;69:221 226. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. Am J Respir Crit Care Med 2002;166:159 165. Manseld DR, Gollogly NC, Kaye DM, Richardson M, Bergin P, Naughton MT. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med 2004;169:361 366. Kaneko Y, Floras JS, Usui K, Plante J, Tkacova R, Kubo T, Ando S, Bradley TD. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 2003;348:1233 1241. Laaban JP, Pascal-Sebaoun S, Bloch E, Orvoe n-Frija E, Oppert JM, Huchon G. Left ventricular systolic dysfunction in patients with obstructive sleep apnea syndrome. Chest 2002;122:1133 1138. Bradley TD, Logan AG, Kimoff RJ, Series F, Morrison D, Ferguson K, Belenkie I, Pfeifer M, Fleetham J, Hanly P, Smilovitch M, Tomlinson G, Floras JS, for the CANPAP Investigators. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 2005;353:2025 2033. Arzt M, Wensel R, Montalvan S, Schichtl T, Schroll S, Budweiser S, Blumberg FC, Riegger GA, Pfeifer M. Effects of dynamic bilevel positive airway pressure support on central sleep apnea in men with heart failure. Chest 2008;134:6166. Oldenburg O, Bitter T, Lehmann R, Korte S, Dimitriadis Z, Faber L, Schmidt A, Westerheide N, Horstkotte D. Adaptive servoventilation improves cardiac function and respiratory stability. Clin Res Cardiol 2011;100:107115. Koyama T, Watanabe H, Kobukai Y, Makabe S, Munehisa Y, Iino K, Kosaka T, Ito H. Benecial effects of adaptive servo ventilation in patients with chronic heart failure. Circ J 2010;74:2118 2124. Kasai T, Usui Y, Yoshioka T, Yanagisawa N, Takata Y, Narui K, Yamaguchi T, Yamashina A, Momomura SI, JASV Investigators. Effect of ow-triggered adaptive servo-ventilation compared with continuous positive airway pressure in patients with chronic heart failure with coexisting obstructive sleep apnea and CheyneStokes respiration. Circ Heart Fail 2010;3:140 148. Westhoff M, Arzt M, Litterst P. Inuence of adaptive servoventilation on B-type natriuretic petide in patients with Cheyne-Stokes respiration and mild to moderate systolic and diastolic heart failure. Pneumologie 2010;64:467 473. Hastings PC, Vazir A, Meadows GE, Dayer M, Poole-Wilson PA, McIntyre HF, Morrell MJ, Cowie MR, Simonds AK. Adaptive servo-ventilation in heart failure patients with sleep apnea: a real world study. Int J Cardiol 2010;139: 17 24. Teschler H, Do hring J, Wang YM, Berthon-Jones M. Adaptive pressure support servo-ventilation: a novel treatment for Cheyne-Stokes respiration in heart failure. Am J Respir Crit Care Med 2001;164:614619. Bitter T, Westerheide N, Hossain MS, Lehmann R, Prinz C, Kleemeyer A, Horstkotte D, Oldenburg O. Complex sleep apnoea in congestive heart failure. Thorax 2011;66:402 407. Hanly PJ, Millar TW, Steljes DG, Baert R, Frais MA, Kryger MH. The effect of oxygen on respiration and sleep in patients with congestive heart failure. Ann Intern Med 1989;111:777 782. Franklin KA, Eriksson P, Sahlin C, Lundgren R. Reversal of central sleep apnea with oxygen. Chest 1997;111:163 169.

Importance and management of chronic sleep apnoea

815d
Gutleben KJ, Bitter T, Karim R, Iber C, Hasan A, Hibler K, Germany R, Abraham WT. Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failure. Eur Heart J 2011; http://dx.doi.org/ 10.1093/eurheartj/ehr298 [Epub ahead of print]. 147. Punjabi NM, Caffo BS, Goodwin JL, Gottlieb DJ, Newman AB, OConnor GT, Rapoport DM, Redline S, Resnick HE, Robbins JA, Shahar E, Unruh ML, Samet JM. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 2009;6:e1000132. 148. Kapur V, Blough DK, Sandblom RE, Hert R, de Maine JB, Sullivan SD, Psaty BM. The medical cost of undiagnosed sleep apnea. Sleep 1999;22:749 755.

143. Brostro m A, Hubbert L, Jakobsson P, Johansson P, Fridlund B, Dahlstro m U. Effects of long-term nocturnal oxygen treatment in patients with severe heart failure. J Cardiovasc Nurs 2005;20:385 396. 144. Phillips BA, Schmitt FA, Berry DT, Lamb DG, Amin M, Cook YR. Treatment of obstructive sleep apnea. A preliminary report comparing nasal CPAP to nasal oxygen in patients with mild OSA. Chest 1990;98:325 330. 145. Puhan MA, Suarez A, Lo Cascio C, Zahn A, Heitz M, Braendli O. Didgeridoo playing as alternative treatment for obstructive sleep apnoea syndrome: randomised controlled trial. BMJ 2006;332:266 270. 146. Ponikowski P, Javaheri S, Michalkiewicz D, Bart BA, Czarnecka D, Jastrzebski M, Kusiak A, Augostini R, Jagielski D, Witkowski T, Khayat RN, Oldenburg O,